Citicoline as Neuroprotector in Neonates Exposed to Hypoxia

Sherief Abd-Elsalam

Status and phase: Enrolling; Phase 3

Conditions: Neonatal Hypoxia

Treatments: Other: Placebo; Drug: Citicoline

Study type: Interventional

Funder types: Other

Identifiers

NCT03949049

neonates tanta

Details and patient eligibility

About

Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Full description

Efficacy of Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial

Enrollment: 40 estimated patients

Sex: All

Ages: Under 1 month old

Volunteers: No Healthy Volunteers

Inclusion criteria

• neonates with hypoxia.

Exclusion criteria

• hypoxic ischemic encephalopathy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 2 patient groups, including a placebo group

Citacoline

Experimental group

Description:

Citacoline as neuroprotector

Treatment:

Drug: Citicoline

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Other: Placebo